xaliproden has been researched along with Multiple Sclerosis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
BourriƩ, B; Bribes, E; Casellas, P; Esclangon, M; Garcia, L; Maffrand, JP; Marchand, J; Thomas, C | 1 |
1 other study(ies) available for xaliproden and Multiple Sclerosis
Article | Year |
---|---|
The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Lipopolysaccharides; Multiple Sclerosis; Naphthalenes; Neuroprotective Agents; Pyridines; Rats; Rats, Inbred Lew; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha | 1999 |